Ami Fadia

“Maybe just on Epidiolex for the DEE trial, can you tell us a little bit about the representation of the different DEE subtypes that you are enrolling in the trial, and what would success look like in the context of data from some competitors that's expected in the coming months as well?”

“Just with regards to the upcoming data readout for Solary Amphidol in binge eating disorder, from a commercial standpoint, what type of profile would be competitive in terms of the efficacy and the safety profile that you're looking to see from the results?”

“Maybe if you can talk about some of the market dynamics with Simbravo and talk about the evolution of the adoption rate there and how do you see that progressing over the coming months.”

“How much data do you need from the Part B of the studies where you're examining how long it takes for patients to, you know, take that second or third or fourth dose before you submit for approval and to be able to, you know, inform the circumstances of re-treatment and the labor, and also how much data do you think…”

“I've got to, just with regards to Vibrance 2, that's going to be presented at the sleep meeting in Baltimore. What additional data on top of what you'd announced at the initial data readout that we can expect at the meeting.”